Full Text Full Text (PDF) Correction (v160,p612) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by McElroy, S. L. Articles by Hudson, J. I. Search for Related Content PubMed Citation Articles by McElroy, S. L. Articles by Hudson, J. I. Eating Disorders Other Somatic Therapy

Topiramate in the Treatment of Binge Eating Disorder Associated With Obesity: A Randomized, Placebo-Controlled Trial

OBJECTIVE: Binge eating disorder is associated with obesity. Topiramate is an antiepileptic agent associated with weight loss. The objective of this study was to evaluate topiramate in the treatment of binge eating disorder associated with obesity. METHOD: For this 14-week, double-blind, flexible-dose (25–600 mg/day) topiramate trial, 61 outpatients (53 women, eight men) with binge eating disorder who were obese (body mass index 30 kg/m²) were randomly assigned to receive topiramate (N=30) or placebo (N=31). The primary efficacy measure was binge frequency. The primary analysis of efficacy was a repeated-measures random regression with treatment-by-time as the effect measure. RESULTS: Compared with placebo, topiramate was associated with a significantly greater rate of reduction in binge frequency, binge day frequency, body mass index, weight, and scores on the Clinical Global Impression severity scale and the Yale-Brown Obsessive Compulsive Scale (modified for binge eating). Topiramate was also associated with significantly greater reductions in binge frequency (topiramate: 94%, placebo: 46%) and binge day frequency (topiramate: 93%, placebo: 46%) and with a significantly higher level of response than placebo. The mean weight loss for topiramate-treated subjects who completed the study was 5.9 kg. Median topiramate dose was 212 mg/day (range=50–600). Nine patients (three receiving placebo, six given topiramate) discontinued because of adverse events. The most common reasons for discontinuing topiramate were headache (N=3) and paresthesias (N=2). CONCLUSIONS: Topiramate was efficacious and relatively well tolerated in the short-term treatment of binge eating disorder associated with obesity.

This article has been cited by other articles:

				D. E. Wilfley, S. J. Crow, J. I. Hudson, J. E. Mitchell, R. I. Berkowitz, V. Blakesley, B. T. Walsh, and The Sibutramine Binge Eating Disorder Research Gro Efficacy of Sibutramine for the Treatment of Binge Eating Disorder: A Randomized Multicenter Placebo-Controlled Double-Blind Study Am J Psychiatry, January 1, 2008; 165(1): 51 - 58. [Abstract] [Full Text] [PDF]

				G. A. Bray and F. L. Greenway Pharmacological Treatment of the Overweight Patient Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184. [Full Text] [PDF]

				D. H. BARZMAN and M. P. DelBello Drs. Barzman and DelBello Reply Am J Psychiatry, March 1, 2007; 164(3): 527 - 528. [Full Text] [PDF]

				B. J. Steinhoff Optimizing therapy of seizures in patients with endocrine disorders Neurology, December 26, 2006; 67(12_suppl_4): S23 - S27. [Abstract] [Full Text]

				J. L. Goren Hyperthyroidism Associated With Topiramate Treatment Psychosomatics, December 1, 2006; 47(6): 529 - 530. [Full Text] [PDF]

				A. L Tata and D. R Kockler Topiramate for Binge-Eating Disorder Associated with Obesity Ann. Pharmacother., November 1, 2006; 40(11): 1993 - 1997. [Abstract] [Full Text] [PDF]

				F. K. Aarsen, E. L.T. van den Akker, S. L.S. Drop, and C. E. Catsman-Berrevoets Effect of topiramate on cognition in obese children. Neurology, October 10, 2006; 67(7): 1307 - 1308. [Full Text] [PDF]

				J. I. Hudson, J. K. Lalonde, J. M. Berry, L. J. Pindyck, C. M. Bulik, S. J. Crow, S. L. McElroy, N. M. Laird, M. T. Tsuang, B. T. Walsh, et al. Binge-eating disorder as a distinct familial phenotype in obese individuals. Arch Gen Psychiatry, March 1, 2006; 63(3): 313 - 319. [Abstract] [Full Text] [PDF]

				J. Yager, M. J. Devlin, K. A. Halmi, D. B. Herzog, J. E. Mitchell, P. S. Powers, and K. J. Zerbe Eating Disorders Focus, October 1, 2005; 3(4): 503 - 510. [Abstract] [Full Text] [PDF]

				R. S. McIntyre and J. Z. Konarski Obesity and Psychiatric Disorders: Frequently Encountered Clinical Questions Focus, October 1, 2005; 3(4): 511 - 519. [Abstract] [Full Text] [PDF]

				J. Yager, M. J. Devlin, K. A. Halmi, D. B. Herzog, J. E. Mitchell, P. S. Powers, and K. J. Zerbe Guideline Watch: Practice Guideline for the Treatment of Patients With Eating Disorders, 2nd Edition Focus, October 1, 2005; 3(4): 546 - 551. [Full Text] [PDF]

				Abstracts FOR SLEEP, SEX, AND EATING DISORDERS Focus, October 1, 2005; 3(4): 554 - 556. [Full Text] [PDF]

				E. Hollander, S. Pallanti, A. Allen, E. Sood, and N. B. Rossi Does Sustained-Release Lithium Reduce Impulsive Gambling and Affective Instability Versus Placebo in Pathological Gamblers With Bipolar Spectrum Disorders? Am J Psychiatry, January 1, 2005; 162(1): 137 - 145. [Abstract] [Full Text] [PDF]

				P. Raskin, P. D. Donofrio, N. R. Rosenthal, D. J. Hewitt, D. M. Jordan, J. Xiang, and A. I. Vinik Topiramate vs placebo in painful diabetic neuropathy: Analgesic and metabolic effects Neurology, September 14, 2004; 63(5): 865 - 873. [Abstract] [Full Text] [PDF]

				J. Korner and L. J. Aronne Pharmacological Approaches to Weight Reduction: Therapeutic Targets J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2616 - 2621. [Full Text] [PDF]

				S. D. Silberstein, W. Neto, J. Schmitt, and D. Jacobs Topiramate in Migraine Prevention: Results of a Large Controlled Trial Arch Neurol, April 1, 2004; 61(4): 490 - 495. [Abstract] [Full Text] [PDF]

				J. L. Brandes, J. R. Saper, M. Diamond, J. R. Couch, D. W. Lewis, J. Schmitt, W. Neto, S. Schwabe, and D. Jacobs Topiramate for Migraine Prevention: A Randomized Controlled Trial JAMA, February 25, 2004; 291(8): 965 - 973. [Abstract] [Full Text] [PDF]

				J. C. Appolinario, J. Bacaltchuk, R. Sichieri, A. M. Claudino, A. Godoy-Matos, C. Morgan, M. T. Zanella, and W. Coutinho A Randomized, Double-blind, Placebo-Controlled Study of Sibutramine in the Treatment of Binge-Eating Disorder Arch Gen Psychiatry, November 1, 2003; 60(11): 1109 - 1116. [Abstract] [Full Text] [PDF]

				Treating Obesity: New Directions Journal Watch Psychiatry, May 22, 2003; 2003(522): 2 - 2. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us